NCT06142929 Micronerves in Dupuytren and the Impact of Its Dissection on Recurrence
| NCT ID | NCT06142929 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Dupuytren's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2024-01-01 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dupuytren disease (DD) is a highly prevalent disabling hand disease. Spontaneous fibrosis nodules and strands in the palms of the hand cause finger contractures in disturbing positions and movement restrictions. Finger movement can be restored by surgery (removing the fibrosis tissue), but recurrence is a major problem and this is difficult to treat. Through microfasciectomy, the presence of small nerve bundles (micronerves) were observed. These nerves are possibly related to the hand fascia, which is the origin of Dupuytren disease. These micornerves and their dissection could play a role in the recurrence of DD. This study will investigate the role of these micronerves in DD, the impact of its dissection on formation of neuromas and on recurrence. Also, the presence of nerve growth factor (NGF) will be evaluated. The purpose is to provide information on potential neuro-induced fibrosis.
Eligibility Criteria
Inclusion criteria: Participants eligible for inclusion in this study must meet all of the following criteria: 1. The participant or his/her legally authorized representative voluntary signed the informed consent prior to the first assessment 2. Participants are ≥ 18 years and diagnosed with primary/recurrent Dupuytren disease 3. Included patients are eligible for microfasciectomy Exclusion criteria: Participants eligible for this study must not meet any of the following criteria: 1. Patients \< 18 years 2. Patient included in an interventional trial with an investigational medicinal product 3. Patients with cognitive impairments, severe rheumatic disease and neurological disorders leading to flexion deformities of the fingers
Contact & Investigator
Ilse Degreef, Prof. Dr.
PRINCIPAL INVESTIGATOR
Universitaire Ziekenhuizen KU Leuven
Frequently Asked Questions
Who can join the NCT06142929 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dupuytren's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06142929 currently recruiting?
Yes, NCT06142929 is actively recruiting participants. Contact the research team at ilse.degreef@uzleuven.be for enrollment information.
Where is the NCT06142929 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT06142929 clinical trial?
NCT06142929 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Ilse Degreef, Prof. Dr. at Universitaire Ziekenhuizen KU Leuven. The trial plans to enroll 80 participants.